## **Proteome Sciences plc**

## (the "Company")

## Holdings in Company and PDMR Shareholding

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Science Fund ("Vulpes"), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that on 28, 29 and 30 December 2016, it purchased 265,000, 250,000 and 350,000 ordinary shares of 1 pence each ("Ordinary Shares") respectively, at an average price of 5.74 pence per Ordinary Share (the "Transaction"). Following the Transaction, Vulpes (and Mr Diggle) have a beneficial interest in 53,838,125 Ordinary Shares, representing approximately 18.29% of the current issued share capital of the Company.

## Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Vulpes Life Science Fund	
2.	Reason for the Notification		
a)	Position/status	Martin Diggle, non-executive director of the Company is a director and partner of Vulpes Life Science Fund	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Proteome Sciences plc	
b)	LEI	n/a	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 1p each	
	Identification code	GB0003104196	
b)	Nature of the transaction	Purchase of Ordinary Shares	
c)	Price(s) and volume(s) 28 December 2016 29 December 2016 30 December 2016	Price(s)	Volume(s)
		5.75p 5.75p 5.725p	265,000 250,000 350,000
d)	Aggregated information: • Aggregated volume • Price	865,000 Ordinary Shares of 1 pence each purchased at an average price of 5.74 pence per Ordinary Share	
e)	Date of the transaction	28 December 2016, 29 December 2016 and 30 December 2016	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	